Peter A. McSweeney

Mesoblast (United States) — United States

Medicine · Health Sciences

61h-index23.8kcitations238works8.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hematopoietic Stem Cell Transplantation(105), CAR-T cell therapy research(33), Systemic Sclerosis and Related Diseases(30), Lymphoma Diagnosis and Treatment(23), Chronic Lymphocytic Leukemia Research(23)

Publications237 total

Remestemcel-L-Rknd (Ryoncil) Improves Survival after Failure of Second-Line Treatment for SR-aGVHD
Transplantation and Cellular Therapy·2026
Myeloablation Followed by Hematopoietic Stem Cell Transplantation and Long‐Term Normalization of Systemic Sclerosis Molecular Signatures
Arthritis & Rheumatology·2024· 4 citedOpen Access
Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids
Bone Marrow Transplantation·2024· 21 citedOpen Access
Remission of severe myasthenia gravis after autologous stem cell transplantation
Annals of Clinical and Translational Neurology·2023· 12 citedOpen Access
5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1)
Blood·2023· 216 citedOpen Access
Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/ Refractory Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of Zuma-1 Cohort 6
Transplantation and Cellular Therapy·2023Open Access
Characterising the autoantibody repertoire in systemic sclerosis following myeloablative haematopoietic stem cell transplantation
Annals of the Rheumatic Diseases·2023· 18 citedOpen Access
Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6
Blood·2022· 6 cited
Myeloablative autologous haematopoietic stem cell transplantation resets the B cell repertoire to a more naïve state in patients with systemic sclerosis
Annals of the Rheumatic Diseases·2022· 13 citedOpen Access
Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study
Journal of Clinical Oncology·2022· 285 citedOpen Access
Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/ Refractory Large B-Cell Lymphoma (R/R LBCL): 1-Year Follow-up of Zuma-1 Cohort 6 (C6)
Transplantation and Cellular Therapy·2022
Lymphocyte subset abnormalities in early severe scleroderma favor a Th2 phenotype and are not altered by prior immunosuppressive therapy
Lara D. Veeken·2022· 10 citedOpen Access
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
New England Journal of Medicine·2021· 493 citedOpen Access
Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study
Blood·2021· 15 cited
Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): One-Year Follow-up of ZUMA-1 Cohort 6 (C6)
Blood·2021· 7 cited
A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects with B-Cell Malignancies
Blood·2021· 19 cited
Clinical and Molecular Findings After Autologous Stem Cell Transplantation or Cyclophosphamide for Scleroderma: Handling Missing Longitudinal Data
Arthritis Care & Research·2021· 9 citedOpen Access
Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma
British Journal of Haematology·2021· 197 citedOpen Access
Outcomes with KTE-X19 in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) in ZUMA-2 who had progression of disease within 24 months of diagnosis (POD24).
Journal of Clinical Oncology·2021· 10 cited
One-Year Follow-up of ZUMA-2, the Multicenter, Registrational Study of KTE-X19 in Patients (Pts) with Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL)
Transplantation and Cellular Therapy·2021· 2 cited
page 1 of 12Next →

Frequent Co-authors

Rainer Storb(30), Brenda M. Sandmaier(21), David G. Maloney(21), Thomas R. Chauncey(18), Michael B. Maris(16), Barry E. Storer(15), Benedetto Bruno(13), Karl G. Blume(11), Richard T. Maziarz(11), Dietger Niederwieser(10), Richard A. Nash(10), Michael A. Pulsipher(10), George E. Georges(8), Mohamed L. Sorror(8), Edward Agura(8), Judith A. Shizuru(7), Ute Hegenbart(7), Amelia Langston(7), Caron A. Jacobson(6), John M. Timmerman(6)